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Partial cranial cruciate ligament 
Tears Treated with stem cell and 
Platelet-rich Plasma combination 
Therapy in 36 Dogs: a retrospective 
study
Sherman O. Canapp Jr.1*, Christopher S. Leasure1, Catherine Cox1, Victor Ibrahim2 and 
Brittany J. Carr1
1 Veterinary Orthopedic & Sports Medicine Group, Annapolis Junction, MD, USA, 2 Regenerative Orthopedic & Sports 
Medicine, Washington, DC, USA
Objective: To evaluate outcomes in 36 dogs with a partial cranial cruciate ligament 
(CCL) tear treated with autologous bone marrow aspirate concentrate (BMAC) or 
adipose-derived progenitor cells (ADPC) with platelet-rich plasma (PRP) combination.
Materials and methods: Medical records of client-owned dogs diagnosed with an 
early partial (≤50%) tear of the craniomedial band of the CCL that was treated with 
BMAC–PRP or ADPC–PRP were reviewed from 2010 to 2015. Signalment, medical 
history, physical and orthopedic examination, objective temporospatial gait analyses, 
radiographs, day 0 and day 90 diagnostic arthroscopy findings, treatment, and outcome 
were among the data collected. A functional owner questionnaire, including the validated 
Helsinki chronic pain index (HCPI), was sent to owners whose dog was known to not 
have had a tibial plateau leveling osteotomy (TPLO). Statistical analysis was performed 
on data, where significance was established at p < 0.05.
results: Stifle arthroscopy findings at 90 days posttreatment were available on 13 of the 
36 dogs. In nine dogs, a fully intact CCL with marked neovascularization and a normal 
fiber pattern was found with all previous regions of disruption healed. One dog revealed 
significant improvement and received an additional injection. The remaining three dogs 
had a >50% CCL tear, and a TPLO was performed. Four additional dogs were known to 
have had a TPLO performed elsewhere. Baseline and day 90 posttreatment objective gait 
analyses were available on 11 of the 36 dogs. A significant difference was found between 
the treated limb total pressure index percent (TPI%) at day 0 and day 90 (p = 0.0124), 
and between the treated limb and contralateral limb TPI% at day 0 (p = 0.0003). No 
significant difference was found between the treated limb and contralateral limb TPI% 
at day 90 (p  =  0.7466). Twelve questionnaires were returned, of which eight were 
Abbreviations: CCL, cranial cruciate ligament; TPLO, tibial plateau leveling osteotomy; TPI%, total pressure index percent; 
ACL, anterior cruciate ligament; MSC, mesenchymal stem cell; BMAC, bone marrow aspirate concentrate; ADPC, adipose-
derived progenitor cells; PRP, platelet-rich plasma; BM-MSC, bone marrow-derived mesenchymal stem cells.
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inTrODUcTiOn
The cranial cruciate ligament (CCL) is necessary to stabilize the 
stifle joint in dogs; however, its rupture is one of the most common 
causes of hind limb lameness and the most common stifle joint 
diseases in dogs (1–3). Surgical intervention is recommended to 
correct the instability, restore the stifle to function, and delay the 
onset of osteoarthritis. Although no specific surgical procedure 
has been established as the gold standard in veterinary medicine, 
intracapsular, extracapsular, and osteotomy techniques are often 
used (4–9). Short- and long-term complications can occur, 
including the progression of osteoarthritis (6, 10–19). While 
these techniques are typically utilized for an unstable stifle, or a 
complete tear, questions still remain as to how to proceed with 
an early partial tear where a functional, stable stifle remains. 
Although an early partial tear is likely to progress to a complete 
tear if left untreated due to the degenerative cascade of effects 
that occurs, the benefits of surgery may not outweigh the risks. 
Therefore, an alternative treatment option could be considered.
Mesenchymal stem cell (MSC) therapy is a more recent cell-
based technique that is being utilized in numerous orthopedic 
conditions. Multipotent progenitor cells and MSCs are two 
types of adult stem cells used for tissue regeneration and their 
trophic effects (20). Found from various sources, including bone 
marrow and adipose tissue, MSCs and progenitor cells have the 
potential to differentiate into multiple cell lineages including 
bone, cartilage, and connective tissue such as ligaments (21, 22). 
Several studies report that MSCs are an optimal source for liga-
ment regeneration due to their high proliferation and collagen 
production potential and ability to quickly differentiate into 
ligament fibroblasts (23, 24).
Numerous animal studies have been conducted to evaluate 
the regeneration potential of MSCs, which have revealed that 
MSCs result in cell engraftment in the CCL, meniscus, and 
cartilage when injected intra-articularly (25, 26). Another 
study found that intra-articularly injected MSCs can accelerate 
the healing of partial anterior cruciate ligament (ACL) tears in 
rats when evaluated biomechanically and histologically (27). 
In this study, in treatment group at 2 and 4 weeks after partial 
transection of the ACL, the transected area was covered with 
healing tissues in which GFP-positive cells were detected (27). 
The treatment group also had better histologic scores at 2 and 
4 weeks and significantly higher ultimate failure load than the 
control group 4 weeks following transection (27). Similar results 
were found in a recent study on rats where 1  week following 
partial transection of the ACL, they received an intra-articular 
injection of either fresh bone marrow cells (BMC) or cultured 
MSCs that were labeled (28). At 4 weeks following injection, the 
cells were not only located within the ACL but the ACL also 
appeared both histologically normal and with more mature 
spindle cells (28). This study also showed that the tensile strength 
in the BMC group reached near normal levels at 4 weeks after 
injection and significantly higher levels of transforming growth 
factor-β1 in the ACL and knee joint fluid in the BMC group 
when compared to the control group at 4 weeks after injection 
(28). A recent study was performed on dogs diagnosed with a 
unilateral unstable CCL rupture that was surgically stabilized, 
which had a contralateral, stable partial CCL (29). At the time 
of surgical stabilization of the unstable stifle, bone marrow-
derived mesenchymal stem cells (BM-MSCs) were collected, 
culture expanded, and subsequently injected intravenously 
and intra-articularly into the contralateral, stable stifle with a 
partial CCL. Inflammatory markers within synovium and serum 
were monitored for 8  weeks and showed that both systemic 
and synovial markers had decreased at 8  weeks postinjection. 
Thus, this study concluded that intra-articular injection of 
autologous BM-MSCs had profound effects on the correlation 
and conditional dependencies of inflammatory markers, which 
could ameliorate the risk of a second CCL rupture (29). Human 
clinical studies show similar potential, where patients have 
shown improvement in objective measures of ACL integrity and 
subjective outcomes after bone marrow MSC injection of grade 
1 through three ACL tears (30). Safety for clinical use has been 
verified with no neoplastic complications (31).
Platelet-rich plasma (PRP) provides growth factors to enhance 
and promote MSC engraftment, providing a synergistic effect. 
Growth factors improve cell proliferation, promote an anabolic 
phase of cells, and stimulate MSC differentiation into fibroblasts 
(32–35). Additionally, PRP provides a three-dimensional scaffold 
for MSCs to facilitate differentiation and cell survival during 
delivery (36). A recent study showed that several intra-articular 
injections of PRP alone indicated evidence of CCL repair and 
remodeling in dogs (37). These findings promote the use of PRP 
in combination with MSCs to aid in ligament healing.
The purpose of this study was to evaluate the use of autologous 
bone marrow aspirate concentrate (BMAC) or adipose-derived 
progenitor cells (ADPC) with PRP combination and a recom-
mended rehabilitation therapy program for the treatment of early 
performance/sporting dogs. Seven of the eight had returned to sport; the remaining dog 
had just begun a return to sport conditioning program 6 months posttreatment. All 12 
respondents believed that their dog had an excellent or very good quality of life and rated 
their dog’s procedural outcome as excellent or good.
conclusion: The use of BMAC–PRP and ADPC–PRP shows promise for the treatment 
of early partial CCL tears in dogs. Further studies are needed and should be randomized, 
blinded, and controlled.
Keywords: bone marrow aspirate concentrate, adipose-derived progenitor cells, platelet-rich plasma, cranial 
cruciate ligament tear, anterior cruciate ligament tear, mesenchymal stem cells, regenerative therapy
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partial CCL tears in dogs. Assessing outcomes in dogs has not 
been previously reported.
MaTerials anD MeThODs
case selection
Medical records of client-owned dogs were reviewed for cases 
diagnosed arthroscopically with an early partial (≤50%) tear of 
the craniomedial band of the CCL that was treated with BMSC–
PRP or ADPC–PRP between January 2010 and December 2015 
at Veterinary Orthopedic & Sports Medicine Group (VOSM). 
Data collected included signalment, medical history, physical 
and orthopedic examination findings, objective temporospatial 
gait analysis findings, diagnostic radiography results, arthroscopy 
findings, treatments, and outcome. Patients with concomitant 
stifle joint problems, or orthopedic or neurologic conditions 
affecting the hind limbs, were excluded from analysis.
Orthopedic examination
Dogs were assessed at baseline and 30, 60, and 90 days posttreat-
ment with an orthopedic and neurologic examination. Degree of 
lameness, presence of stifle effusion, presence of cranial drawer 
and cranial tibial thrust in flexion and extension, and McMurray 
test result were among the findings recorded (38). Additional 
abnormal orthopedic or neurologic findings were also recorded.
Objective gait analysis
Objective gait analysis was performed at baseline and 90  days 
posttreatment in a quiet room using a temporospatial pressure 
sensing walkway. The walkway system was equipped with an 
8.23 m × 0.85 m portable mat with 29,952 encapsulated sensors 
(GaitFour Pressure Sensing Walkway, platinum version, CIR 
Systems Inc., Havertown, PA, USA). The active dimensions of 
the mat were 8.04  m ×  0.61  m. A 1.25  m ×  0.85  m section of 
inactive mat was placed at each end of the walkway system to 
provide transition surfaces when entering and exiting the system. 
The mat was calibrated by the manufacturer. The walkway system 
interfaced with a computer and software program for process-
ing and storing raw data recorded from quadruped gait analysis 
(GaitFour, platinum version, CIR Systems Inc., Havertown, PA, 
USA). One camera was positioned at a height of 50 cm at the end 
of the walkway system to record movement (Logitech mega pixel 
web camera, Logitech, Freemont, CA, USA). Digital video files of 
each pass across the walkway system were automatically linked to 
the data files for footfall verification.
Each dog was familiarized with the room prior to walking on 
the mat and was handled by the same examiner. Dogs were made 
to walk on the mat until they appeared relaxed, approximately 
four to six passes per dog. Three passes were recorded at both a 
walk and a trot, where a pass was defined as a dog moving along 
the length of the walkway in one direction for four to six gait 
cycles. A satisfactory pass consisted of minimal head turning, a 
walk velocity of 0.9–1.2 m/s or trot velocity of 1.8–2.6 m/s, and 
less than two standard deviations in gait cycle velocity differences. 
The software program identified the paw print of each footfall 
and analyzed multiple variables for each pass. The data calculated 
for each pass provided the total pressure index percent (TPI%) 
(sum of peak pressure values recorded from each activated sensor 
by a paw during mat contact/total sum of peak pressure values 
for all feet × 100). The TPI% of the treated limb was compared 
to the TPI% of the contralateral limb at baseline and at 90 days 
posttreatment. The TPI% of the treated limb at day 0 was also 
compared to the treated limb TPI% at 90  days posttreatment. 
Dogs diagnosed with bilateral partial CCL tears were excluded 
from this analysis.
radiographs
Routine lateral and craniocaudal radiographs were performed of 
both stifles in all patients at baseline and evaluated for evidence of 
stifle osteoarthritis by a board-certified veterinary surgeon (39).
Diagnostic stifle arthroscopy
A standard parapatellar portal was utilized for arthroscopic 
evaluation of the stifle. The stifle was clipped and aseptically 
prepared and a 22-gauge needle was placed into the lateral 
compartment. Synovial fluid was aspirated using a 5 ml syringe 
to ensure that the needle was in the joint. Approximately 10 ml 
of sterile saline solution was injected into the stifle to distend 
the joint. A  15 blade was used to create medial and lateral 
parapatellar stab incisions to allow insertion of the cannula 
and trochar into the stifle. A 1.9 or 2.7  mm arthroscope was 
inserted into the cannula, depending on the size of the dog. 
The stifle joint was explored arthroscopically and assessed all 
structures, including the craniomedial and caudolateral band of 
the CCL, the caudal cruciate ligament, and medial and lateral 
menisci. Cartilage breakdown was scored using the Outerbridge 
classification (40). The fat pad was not removed with a shaver, 
but rather an L-shaped probe (Graduated Black Probe 2.5 mm 
tip length, Arthrex Vet Systems, Naples, FL, USA) was inserted 
and used to move the fat pad for direct observation of the CCL. 
The torn portion (percent) of the CCL was measured using the 
standardized L probe. If ≤50% of the craniomedial band of the 
CCL was determined to be damaged, a BMAC–PRP or ADPC–
PRP injection was to be performed. If a >50% tear was observed, 
a tibial plateau leveling osteotomy (TPLO) was performed. The 
arthroscopic incisions were closed routinely.
Bone Marrow collection for BMac
The dog was placed in lateral recumbency, and the hip was clipped 
and aseptically prepared. The vaclock syringe and bone marrow 
aspiration needle were primed with 20 ml of heparin 1,000 U/ml, 
leaving 5 ml in the vaclock syringe. A 15 blade was used to create 
a 0.5 cm stab incision at the point of the proximal femur and an 
11 gauge × 110 mm bone marrow aspiration needle was inserted 
into the greater trochanter. Approximately 30 ml of bone marrow 
was obtained. The incision was closed routinely.
Blood collection for PrP with BMac
The jugular vein was clipped and aseptically prepared. An 
18-gauge butterfly needle was used to collect 50 ml of blood into 
a 60  ml syringe that contained 10  ml of anticoagulant citrate 
dextrose solution A (ACD-A).
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BMac and PrP Processing
Bone marrow was processed using a validated system according 
to manufacturer’s protocols (BMC Stem Cell Kit, Companion 
Regenerative Therapies, Newark, DE, USA). Briefly, the 150–170-
µm filter, 60-ml syringe, and concentrating device were primed 
with heparin 1,000 U/ml. The vaclock syringe containing the bone 
marrow was attached to the filter and injected through the filter to 
the empty 60 ml syringe. The bone marrow was then injected into 
the concentrating device, placed into the centrifuge (Executive 
Series Centrifuge II, Companion Regenerative Therapies, 
Newark, DE, USA), and spun for 10  min at 3,600  RPM. After 
centrifugation, a 60-ml syringe was used to aspirate the plasma 
layer. A 12-ml syringe was then used to aspirate 3 ml of BMAC. 
Approximately 30,000 MSCs were present in the initial 30-ml 
bone marrow sample (41).
Whole blood was processed using a validated system accord-
ing to manufacturer’s protocols (PurePRP® Kit, Companion 
Regenerative Therapies, Newark, DE, USA). Briefly, the syringe 
containing the blood and ACD-A was injected into the first 
concentrating device, placed into the centrifuge (Executive Series 
Centrifuge II, Companion Regenerative Therapies, Newark, DE, 
USA), and spun for 1 min at 3,600 RPM. After centrifugation, a 
60-ml syringe was used to aspirate the platelet plasma suspension 
layer and was then injected into the second concentrating device. 
The concentrating device was placed into the centrifuge and spun 
for 5 min at 3,800 RPM. After centrifugation, a 60-ml syringe was 
used to aspirate the plasma until the aspirating disc reached the 
bottom of the tube. A 12-ml syringe was used to inject 10 ml of 
air into the device to allow for re-suspension of the platelets at 
the base of the device. The device was swirled to re-suspend the 
platelets into the remaining plasma. The 12-ml syringe was then 
used to aspirate 4 ml of PRP.
To confirm the PRP product composition, a baseline blood 
and PRP product WBC differential, RBC concentration, and 
platelet concentration were obtained on all dogs using an in-
house hematology analyzer that had been calibrated according to 
manufacturer standards (Idexx LaserCyte Hematology Analyzer, 
Idexx Laboratories, Westbrook, ME, USA). The PRP obtained 
a sixfold to sevenfold increase in platelets, 85% reduction in 
neutrophils, and 95% reduction in red blood cells from whole 
blood. Platelet, neutrophil, and red blood cell counts were verified 
prior to use.
adipose collection for aDPc
The abdomen was clipped and aseptically prepared. A 4-cm inci-
sion was made in midline in the cranial abdomen, and a 2-cm 
incision was made through the linea. The falciform ligament was 
identified. Approximately 20  g of falciform adipose tissue was 
placed into a sterile container with Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with fetal bovine serum, peni-
cillin, and streptomycin. The incision was closed routinely.
Blood collection for PrP with aDPc
The jugular vein was clipped and aseptically prepared. An 
18-gauge butterfly needle was used to collect 25 ml of blood into 
a 30 ml syringe that contained 5 ml of citrate phosphate dextrose 
adenine anticoagulant.
aDPc and PrP Processing
Adipose and blood samples were shipped in validated shipping 
boxes at 4°C to the Virginia Tech Marion DuPont Scott Equine 
Medical Center Regenerative Medicine Service for processing. 
ADPC and ACS were processed using their proprietary protocols. 
Briefly, adipose was mechanically and enzymatically separated to 
release ADPCs. The cells were then washed in phosphate-buffered 
saline (PBS), and nucleated cells were counted and cultured in 
stem cell media at 37°C in a 5% CO2 incubator with 95% humid-
ity. Cells were washed in PBS once at 70% confluency, trypsinized, 
and suspended in PRP. Approximately 5  million ADPCs were 
present in the sample, which were verified prior to suspension. 
PRP was prepared via centrifugation to obtain a fourfold increase 
in platelets and 80% reduction in white blood cells from whole 
blood. Platelet and white blood cells counts were verified prior to 
use. The ADPC–PRP was shipped to VOSM in validated shipping 
boxes at 4°C for subsequent injection.
intra-articular injection of BMac–PrP 
or aDPc–PrP
Bone marrow aspirate concentrate and PRP were drawn into an 
empty syringe in a 1:1 ratio via a three-way stopcock. The stifle 
was clipped (if ADPC–PRP) and aseptically prepared. A 22-gauge 
needle was placed into the lateral compartment of the stifle and 
synovial fluid was aspirated using a 5-ml syringe to ensure the 
needle was in the joint. Approximately 2–4 ml of BMAC–PRP 
or 1–2  ml of ADPC–PRP was injected intra-articularly into 
the stifle; volume depended on the size of the dog. If the dog 
was below 15 kg in weight, they received 2 ml of BMAC–PRP 
or 1  ml of ADPC–PRP. If the dog was above 15  kg in weight, 
they received 4  ml of BMAC–PRP or 2  ml of ADPC–PRP. All 
dogs were placed into a soft-padded bandage for 12–24 h. Once 
the soft-padded bandage was removed, dogs were placed into 
a custom stifle orthotic that had been previously molded and 
constructed (Animal Orthocare, LLC, Chantilly, VA, USA) if the 
owner was concerned about their ability to confine and control 
their dog or if increased laxity had been noted on palpation at 
the initial examination. All owners were instructed to discontinue 
NSAIDs, corticosteroids, or anti-inflammatory supplements at 
least 2 weeks prior to injection. Owners were given the option 
to choose between BMAC–PRP and ADPC–PRP. The option to 
bank culture-expanded ADPCs and blood at the Virginia Tech 
Marion DuPont Scott Equine Medical Center was conveyed to the 
owner, while BMAC would not typically be banked. BMAC–PRP 
treatment would be performed the same day as stifle arthroscopy, 
while ADPC–PRP treatment would occur approximately 2 weeks 
after being sent for culture, which may play into the decision for 
owners that traveled a long distance to VOSM. Following the 
collection procedure and/or injection, patients were placed on 
tramadol (3–4 mg/kg by mouth every 8 h) or codeine (1–2 mg/
kg by mouth every 8 h) for 3 days. The cost of each treatment 
was equal.
Posttreatment rehabilitation Therapy
All patients were instructed to enroll in formal rehabilitation 
therapy following treatment consisting of once weekly manual/
massage therapy, class IIIb low-level laser therapy for the affected 
TaBle 1 | helsinki chronic pain index for veterinary use, total points: 36.
Question asked 0 Points 1 Point 2 Points 3 Points 4 Points
Rate your dog’s mood Very alert Alert Neither alert nor indifferent Indifferent Very indifferent
Rate your dog’s willingness to participate in play Very willing Willing Reluctantly Very reluctantly Does not play at all
Rate your dog’s vocalization (audible complaining) Never Hardly ever Sometimes Often Very often
Rate your dog’s willingness to walk Very willing Willingly Reluctantly Very reluctantly Does not walk at all
Rate your dog’s willingness to trot Very willing Willingly Reluctantly Very reluctantly Does not trot at all
Rate your dog’s willingness to gallop Very willing Willingly Reluctantly Very reluctantly Does not gallop at all
Rate your dog’s willingness to jump (e.g., into car,  
onto sofa)
Very willing Willingly Reluctantly Very reluctantly Does not jump at all
Rate your dog’s ease in lying down With great ease Easily Neither easily nor difficultly With difficulty With great difficulty
Rate your dog’s ease in rising from a lying position With great ease Easily Neither easily nor difficultly With difficulty With great difficulty
Rate your dog’s ease of movement after long rest With great ease Easily Neither easily nor difficultly With difficulty Very often/always 
difficulty
Rate your dog’s ease of movement after major  
activity or heavy exercise
With great ease Easily Neither easily nor difficultly With difficulty Very often/always 
difficulty
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stifle (5 J/cm2) and a twice daily at home exercise program for 
the first 8  weeks. NSAIDs, corticosteroids, anti-inflammatory 
supplements, class IV low level laser therapy, therapeutic ultra-
sound, hydrotherapy, and TENS/NMES were not permitted for 
the first 8 weeks posttreatment as their effect on stem cell and 
PRP therapy is still not fully known.
Validated Functional Questionnaire
An owner questionnaire, including the validated Helsinki 
chronic pain index (HCPI), was e-mailed to all owners whose 
dog was known to not have had surgical repair following 
treatment. The questionnaire inquired about duration of lame-
ness following treatment, if their performance/sporting dog 
returned to sport, and if so at what level compared to prior 
to injury. To assess the dog’s current well-being, owners were 
asked to rate their dog’s quality of life in the last 7 days (excel-
lent, very good, good, fair, poor) and were asked their opinion 
of their dog’s procedural outcome (excellent, good, fair, poor). 
Possible chronic pain was assessed with the validated HCPI 
that contained questions on the dog’s mood, lameness, and 
willingness to move, play, and jump. The HCPI contained 11 
questions whose answers were later given a value (0–4), giving 
a total index score range of 0–44. Individual question scores of 
0 and 1 indicate normal behavior and movement, where scores 
of 2, 3, and 4 indicate pain with increasing severity. Therefore, 
healthy dogs usually have an HCPI between 0 and 11, and dogs 
with chronic pain will have a score of 12–44. The HCPI has 
been validated, reliability tested, and responsiveness tested (42, 
43) (Table 1).
statistical analysis
Data analyses were performed using a statistical software pro-
gram (GraphPad Prism version 6.00, GraphPad Software, La 
Jolla, CA, USA). Gait analysis data were analyzed using a paired 
t-test that accounts for correlations between paired observa-
tions. A paired t-test will result in increased statistical power 
to detect a treatment effect when compared to an independent 
t-test. Outcome versus percent tear contingency data were 
analyzed using the Chi-square test for trend. Outcome versus 
use of a custom stifle orthotic contingency data were analyzed 
using the Fisher’s exact test. Outcome versus type of treatment 
(BMAC–PRP or ADPC–PRP) received contingency data were 
analyzed using a Fisher’s exact test. All the results were consid-
ered significant at p < 0.05.
resUlTs
signalment
In accordance with AAALAC International Rules of 
Accreditation, this study was performed with the approval of 
the VOSM Research Committee and with owner’s consent. All 
clients volunteered their dog for the study and provided writ-
ten consent as required by Veterinary Orthopedic and Sports 
Medicine Group for every study participant. Medical records of 
36 dogs diagnosed with an early partial (≤50%) CCL tear that 
were treated with BMSC–PRP or ADPC–PRP were reviewed. 
Ages ranged from 1 year to 9.5 years (mean 4.8 years, median 
4.7 years), with 18 dogs being female (6 intact) and 18 dogs being 
male (12 intact). Body weights ranged from 4.8 to 60.5 kg (mean 
25.9  kg, median 22.6  kg). Breeds included 10 (27.8%) Border 
Collies, 6 (16.7%) Labrador Retrievers, 3 (8.3%) Australian 
Shepherds, 2 (5.6%) Golden Retrievers, 2 (5.6%) Pembroke Welsh 
Corgis, 2 (5.6%) Shelties, and 1 (2.8%) of each of the following: 
Akbash, Basset Hound, Bull Terrier, Dutch Shepherd, German 
Shorthaired Pointer, Giant Schnauzer, Gordon Setter, Irish Setter, 
Keeshond, Mixed Breed, and Portuguese Water Dog. The major-
ity of dogs were performance/sporting dogs [26 (72%) versus 10 
(28%)] that were a companion dog only (Table 2). Duration of 
lameness ranged from 3 days to 4 years. Nineteen cases received 
BMAC–PRP for treatment, while 17 cases received ADPC–PRP. 
A custom stifle orthotic was used posttreatment in 14 dogs to 
prevent damage to the CCL during the recovery period.
Orthopedic examination
Baseline orthopedic examination findings were available in 30 of 
the 36 dogs. A weight-bearing lameness and shortened stride was 
noted in 29 dogs, while 1 dog had a shortened stride only. On 
palpation, very mild effusion was present in the affected limb of 
1 dog, mild effusion was present in 11 dogs, moderate effusion in 
17 dogs, and 1 dog had no effusion. McMurray test for meniscal 
evaluation was negative in 29 dogs, while 1 dog was positive. Mild 
cranial drawer and tibial thrust were noted in flexion only in the 
FigUre 2 | a statistically significant difference was found between 
the treated limb and contralateral limb total pressure index percent 
(TPi%) at day 0 (p = 0.0003) (solid line, mean; dotted line, normal 
TPi%).
TaBle 2 | Patient occupation breakdown.
Occupation number of dogs
Companion 10
Performance/sport 26
 Agility 15
 Conformation 3
 Flyball 3
 Hunting 3
 Herding 2
 Obedience 2
 Field trial 1
 Search and rescue 1
 Service dog 1
FigUre 1 | a statistically significant difference was found between 
the treated limb total pressure index percent (TPi%) at day 0 and day 
90 (p = 0.0124) (solid line, mean; dotted line, normal TPi%).
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affected limb in 23 dogs. Palpable evidence of stifle instability was 
absent in seven dogs.
radiographs
Baseline radiograph findings were available in 30 of the 36 dogs. 
Very mild joint effusion was noted in the affected limb of 3 dogs, 
mild effusion in 12 dogs, and moderate effusion in 14 dogs. One 
dog had no effusion present on radiographs. Osteoarthritis was 
also present on radiographs in the affected limb of five dogs. 
Joint effusion was noted in the contralateral limb in 15 dogs, with 
osteoarthritis being present in 1 (39).
Objective gait analysis
Both baseline and day 90 posttreatment objective gait analyses 
were available on 11 of the 36 dogs. Mean baseline TPI% was 
17.7% (median 17.9%, range 13.1–22.8%) in the affected limb 
and 21.7% (median 21.5%, range 18.8–24.3%) in the unaffected 
limb. At 90 days posttreatment, mean TPI% was 20.1% (median 
20.2%, range 16.9–22.8%) in the treated limb and 19.9% (median 
19.2%, range 17.3–22.9%) in the contralateral limb. The TPI% of 
the treated limb was compared to the TPI% of the contralateral 
limb at baseline and at 90 days posttreatment. The TPI% of the 
treated limb at day 0 was also compared to the TPI% of the 
treated limb at 90 days posttreatment. A statistically significant 
difference was found between the treated limb TPI% at day 0 
and day 90 (Figure 1; p = 0.0124), and between the treated limb 
and contralateral limb TPI% at day 0 (Figure 2; p = 0.0003). No 
significant difference was found between the treated limb and 
contralateral limb TPI% at day 90 (Figure 3; p = 0.7466).
Diagnostic stifle arthroscopy
Baseline diagnostic stifle arthroscopy findings were available on 
all 36 dogs. Diagnosis was confirmed and the CCL was found 
to be partially torn unilaterally in 35 dogs (13 left, 22 right), 
and bilaterally in 1 dog. The dog with bilateral partial CCL 
tears was omitted from the study, and the other 35 dogs were 
included in this study. A percent tear of the craniomedial band 
of the CCL was recorded for each dog. The high end was used 
to calculate descriptive statistics where a range was reported. 
Mild fraying of the craniomedial band of the CCL was reported 
in 4 of the 35 dogs. The percent tear of the craniomedial band 
of the CCL ranged from 5 to 50% (mean 20.8%, median 20%) in 
the remaining 31 dogs (Figure 4). The meniscus was found to 
be intact in 34 dogs, whereas 1 dog was found to have a bucket 
handle tear of the caudal pole of the medial meniscus, and a 
partial meniscectomy of the medial meniscus was performed. 
Degenerative joint disease (DJD) findings were recorded in 31 
of the 35 dogs. Very mild DJD was reported in 2 dogs, mild DJD 
was reported in 4 dogs, moderate DJD in 2 dogs, and no DJD 
was found in the remaining 23 dogs.
Stifle arthroscopy findings at 90  days posttreatment were 
available on 13 of the 35 dogs. In 9 of the 13 dogs, a fully intact 
CCL with marked neovascularization and a normal fiber pat-
tern was found with all previous regions of disruption healed. 
It appeared that the blood supply to the region of CCL injury 
was coming from the genicular artery (Figure 5). One dog was 
found to have significantly improved by way of an intact CCL 
with minor fraying, compared to a 25% tear of the craniomedial 
FigUre 5 | representative images of a fully intact cranial cruciate 
ligament with marked neovascularization and a normal fiber pattern 
with all previous regions of disruption healed at the day 90 
posttreatment stifle arthroscopy.
FigUre 4 | representative image of an early partial tear of the 
craniomedial band of the cranial cruciate ligament at the baseline 
stifle arthroscopy.
FigUre 3 | no significant difference was found between the treated 
limb and contralateral limb total pressure index percent (TPi%) at day 
90 (p = 0.7466) (solid line, mean; dotted line, normal TPi%).
TaBle 3 | Veterinary Orthopedic & sports Medicine group return to 
agility grading scale.
Description grade
Dog did not return to agility for reason unrelated to surgery 1
Dog was physically unable to return to agility 2
Dog returned to agility and performed worse than preoperative level 3
Dog returned to agility and performed at the preoperative level 4
Dog returned to agility and performed better than preoperative level 5
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band of the CCL at baseline, and received an additional injec-
tion. The dog was found to have normal range of motion and no 
discomfort, tibial thrust, or lameness 90  days after the second 
injection. The remaining three dogs were found to have a >50% 
tear (either progressive since baseline or completely ruptured), 
and a TPLO was performed at VOSM. Four additional dogs were 
reported by the owner to have had a TPLO performed outside 
of VOSM.
Validated Functional Questionnaire
Questionnaires were sent to all owners whose dog was known 
to not have had surgical repair following treatment (29 dogs). 
Questionnaires were returned for 12 dogs (41%), 6 of which had 
received ADPC–PRP and 6 of which had received BMAC–PRP. 
Follow-up time between surgery and the questionnaire ranged 
from 0.5 to 2.9 years (mean 1.8 years, median 1.9 years). HCPI 
ranged from 0 to 17 (mean 4.4, median 1, standard deviation 6.3). 
Owners were asked how long their dog experienced lameness fol-
lowing treatment; the answers ranged from 0 to 12 months (mean 
2.4 months, median 1.3 months). All 12 respondents believed their 
dog had an excellent (10) or very good (2) quality of life in the last 
7 days and rated their dog’s procedural outcome as excellent (11) 
or good (1). Of the 12 questionnaires returned, 8 were reported 
to be performance/sporting dogs. According to the owner, seven 
of the eight dogs had returned to sport; the remaining dog had 
just begun a return to sport conditioning program 6 months post-
treatment. Of the seven dogs that returned to sport, five dogs were 
reported to be competing at the same level compared to prior to 
injury, and two dogs were competing at a greater level compared 
to prior to injury (including faster times, higher jump height, 
and dropping bars less). According to the previously established 
VOSM Return to Agility Grading Scale (Table 3), of the four dogs 
that competed in agility, two dogs (50%) were grade 4 and two 
dogs (50%) were grade 5. Of the seven dogs that returned to sport, 
it was found that the greatest amount of time a dog had been 
competing since their procedure was 2.5 years.
comparisons
The seven reported failures were found to have had a 50% (1), 
25% (1), 20% (1), and 10% (4) tear at baseline. There was no 
association found between outcome and the percent tear reported 
at baseline (p = 0.5545). A custom stifle orthotic was used post-
treatment in 14 dogs, with 4 of the reported failures having used 
an orthotic, and 3 failures not having used an orthotic. There was 
no association found between outcome and the use of an orthotic 
posttreatment (p = 0.5545). There were four reported failures that 
received ADPC–PRP treatment and three failures that received 
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BMAC–PRP treatment. There was no association found between 
outcome and the treatment type received (p = 0.6843). All seven 
dogs that failed went on to have a TPLO procedure.
DiscUssiOn
In this study, we investigated the use of autologous BMAC–PRP 
or ADPC–PRP combination for the treatment of early partial 
CCL tears in dogs and found that both provide promising 
potential for clinical use, which was supported by objective gait 
analysis, diagnostic arthroscopy, and validated functional ques-
tionnaire. Our results support the findings of previous studies 
in which MSCs engrafted to the CCL (27, 28) and when intra-
articularly injected have been found to accelerate the healing 
of partial ACL tears in rats (30, 31). It is unknown if the MSCs 
used in our study engrafted in order to regenerate the CCL. 
Furthermore, our results demonstrate the clinical relevancy of 
these previous findings in dogs and provide further evidence 
to support clinical findings found in a previously reported case 
series in humans (32). Additionally, the questionnaire revealed 
that the greatest amount of time a dog had been competing since 
their procedure was 2.5 years, demonstrating that the CCL is 
able to withstand the continued rigor of sport.
The main limitations of this study are related to the nature of 
a retrospective study, including variation in treatments and reha-
bilitation therapy, loss to follow-up, and incomplete documenta-
tion. Most owners and patients whose data were collected for 
this study traveled from out of state for diagnosis and treatment, 
several being from across the country, thereby potentially con-
tributing to the loss to follow-up and lack of follow-up findings. 
This element may also have played a role in the treatment type 
chosen by the owner. A greater return in questionnaires would 
be beneficial, thus positively or negatively affecting the outcomes 
associated with the survey, including the HCPI, the owner’s 
opinions on outcome, and the rate of dogs that returned to sport. 
Additionally, owner compliance to rehabilitation therapy recom-
mendations was unknown. No associations that may provide 
a possible cause or correlation to treatment outcome could be 
deduced. Owner compliance to the strict at home confinement 
restrictions and guidelines given posttreatment are unknown 
and therefore may play a factor. Unfortunately, the exact stem 
cell numbers injected are unknown, which is a limitation of 
this study. However, previous validation work shows that there 
are approximately 5  million ADPC versus 30,000 BMAC (44). 
In spite of the large discrepancy in cell numbers between the 
ADPC and BMAC, it was determined that neither treatment was 
superior to the other in terms of outcome. Therefore, it appears 
that both treatment types possess the ability to regenerate the 
CCL; however, the cell number required still remains unknown. 
Additionally, difference in platelet concentration between the 
two systems used could affect outcome, and it is unclear what 
effect this had on outcomes for this study. Finally, because our 
standard of care is to utilize a stem cell and PRP combination, 
it is still unknown if stem cells or PRP alone could produce the 
same results.
In conclusion, our study provides promise to the use of 
autologous BMAC–PRP or ADPC–PRP combination as an 
alternative treatment option. However, further studies are needed 
to determine if they are reproducible in a well-populated rand-
omized, blinded, and controlled trial, reporting data from BMAC 
and ADPC separately. Cell counts and biomarker assays should 
be included in future studies. Clinical findings and a validated 
functional questionnaire should be documented before and after 
treatment.
eThics sTaTeMenT
This was a retrospective study and only gathered data from 
previously performed treatments on client-owned dogs. In 
accordance with AAALAC International Rules of Accreditation, 
this study was performed with the approval of the VOSM 
Research Committee and with owner consent. All clients vol-
unteered their dog for the study and provided written consent 
as required by Veterinary Orthopedic and Sports Medicine 
Group for every study participant. All clients volunteered their 
dog for the study and provided written consent as required by 
Veterinary Orthopedic and Sports Medicine Group for every 
study participant.
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